Biologic activity of tamoxifen at low doses in healthy women

Andrea Decensi, Bernardo Bonanni, Aliana Guerrieri-Gonzaga, Sara Gandini, Chris Robertson, Harriet Johansson, Roberto Travaglini, Maria Teresa Sandri, Antonella Tessadrelli, Gabriel Farante, Federica Salinaro, Donato Bettega, Antonina Barreca, Peter Boyle, Alberto Costa, Umberto Veronesi

Research output: Contribution to journalArticle

Abstract

Background: Results of a clinical trial recently completed in the United States indicate that administration of tamoxifen (20 mg/day) to women at risk can reduce breast cancer incidence by approximately 50% but is associated with an increased risk of developing endometrial cancer and venous thromboembolic events. Since these adverse effects may be dose related, we investigated the effect of tamoxifen on several biomarkers when the drug was given at doses lower than those currently in use. Methods: In two sequential experiments, 127 healthy hysterectomized women aged 35-70 years were randomly assigned to one of the following four treatment arms: placebo (n = 31) or tamoxifen at 20 mg/day (n = 30) (first experiment); or tamoxifen at 10 mg/day (n = 34) or tamoxifen at 10 mg/alternate days (n = 32) (second experiment). Baseline and 2-month measurements of the following parameters were compared: 1) total cholesterol (primary end point) and other surrogate markers of cardiovascular disease, e.g., low-density lipoprotein cholesterol, high- density lipoprotein cholesterol, triglycerides, and lipoprotein(a); 2) blood cell count; 3) fibrinogen; 4) anti-thrombin III; 5) osteocalcin; and, 6) in a subgroup of 103 women, insulin-like growth factor-I (IGF-I), a possible surrogate marker for breast cancer. Results. After adjustment for the baseline values, there were reductions in circulating levels of total cholesterol and IGF-I of the same magnitude in all three tamoxifen treatment arms. A similar pattern was observed for most of the other parameters. In the placebo arm, fibrinogen level, which showed a decrease, was the only parameter exhibiting change. Conclusions: Up to a 75% reduction in the conventional dose of tamoxifen (i.e., 20 mg/day) does not affect the activity of the drug on a large number of biomarkers, most of which are surrogate markers of cardiovascular disease. This study was hypothesis generating, and larger studies are warranted to assess the efficacy of tamoxifen at low doses.

Original languageEnglish
Pages (from-to)1461-1467
Number of pages7
JournalJournal of the National Cancer Institute
Volume90
Issue number19
Publication statusPublished - Oct 7 1998

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Biologic activity of tamoxifen at low doses in healthy women'. Together they form a unique fingerprint.

  • Cite this

    Decensi, A., Bonanni, B., Guerrieri-Gonzaga, A., Gandini, S., Robertson, C., Johansson, H., Travaglini, R., Sandri, M. T., Tessadrelli, A., Farante, G., Salinaro, F., Bettega, D., Barreca, A., Boyle, P., Costa, A., & Veronesi, U. (1998). Biologic activity of tamoxifen at low doses in healthy women. Journal of the National Cancer Institute, 90(19), 1461-1467.